No one is going to buy Affymax. Only asset it has is "blue sky" Takeda deal.
No entity will buy the Affymax company and pay shareholders. To do so would bring along all of the headaches, time, energy and expense of the products liability and securities litigation. The ONLY ASSET it has that anybody may be interested in buying would be the "blue sky" Takeda royalties/milestone deal for the recalled and disgraced Omontys drug. But Omontys itself is beset with problems: No unmet medical need; cannot be approved for CKD patients generally; industry standard Epogen/Arnasep with proven safety profiles; biosimilars soon to be on the market; and a disgraced reputation, among others. I predict a bankrupt Affymax will sell the Takeda deal in its Chapter 11 reorganization and set aside sales proceeds for the litigation claims.
It is an UNMET medical need due to price gauging by AMGN's drugs.
I'm pretty confident Roche is patiently waiting to enter to this market, due to some Patent issues they could not.
They will make a run if it were to occur. Just for patents alone someone will go ahead and bid. Takeda got into this space, due to its high potential. Someone will throw in few 100 millions just to get a handle on it.
You said it is going to BK on Monday when the Website was down for maintenance reasons.